Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 3/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 3/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | PDE4A | P27815 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCND2 | P30279 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 3/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1570314 | 0.90 | IKBKB (0.45) | SYKIGF1RGPR119IKBKBPDE4A | |
| SCHEMBL1633896 | 0.87 | TBK1 (0.48) | SYKIGF1RGPR119JAK2TBK1 | |
| SCHEMBL1572268 | 0.85 | IGF1R (0.43) | IGF1RGPR119IKBKBPDE4APDE4B | |
| SCHEMBL1570949 | 0.85 | TBK1 (0.46) | IGF1RGPR119IKBKBJAK2TBK1 | |
| SCHEMBL3320965 | 0.85 | IGF1R (0.42) | CHEK2SYKIGF1RGPR119IKBKB | |
| SCHEMBL1572127 | 0.84 | EGFR (0.46) | IGF1RIKBKBJAK2MAPTJAK3 | |
| SCHEMBL13336350 | 0.83 | IGF1R (0.41) | SYKIGF1RIKBKBPDE4APDE4B | |
| SCHEMBL1872243 | 0.83 | GPR119 (0.44) | CHEK2IGF1RGPR119IKBKBJAK2 | |
| SCHEMBL3320678 | 0.82 | TBK1 (0.39) | SYKIGF1RIKBKBJAK2TBK1 | |
| SCHEMBL13336352 | 0.81 | JAK2 (0.44) | IGF1RIKBKBPDE4BJAK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | JAIN RAMA | 2010-05-13 | — | — | US | disclosed |
| WO-2009153313-A1 | 2 -ARYLAMINOQUINAZOLINES FOR TREATING PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100121052-A1 | Novel compounds for treating proliferative diseases | PDK1, PDK2, PDK3 | CHEK2 287/4885SYK 4070/4885IGF1R 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.